IBA, a provider of proton therapy solutions for the treatment of cancer, announces the delivery of its first large field-of-view cone-beam CT (CBCT) system at the Willis Knighton Health System, Shreveport, Louisiana in readiness for commissioning.
With its large field-of-view CBCT, IBA is the only proton therapy provider able to obtain volumetric imaging at isocenter with a field of view of 50 cm, reported a company press release. The previous standard was 26cm. This improvement will further improve patient positioning and, thus, the precision of treatment. Furthermore, it enables unique opportunities for adaptive therapy by improved tracking of the proton path, starting from the patient skin through to the target tumor volume. This is especially useful for indications such as breast and pelvis.
The large-field-of-view capability is now available on IBA’s ProteusONE** and ProteusPLUS* solutions, and will be also installed at the following centers; Texas Center for Proton Therapy, Beaumont Health System, Baptist Health South Florida, and Groningen Proton Therapy Center.
Frederic Genin, Chief Product & Marketing Officer Proton Therapy at IBA said: “Offering solutions that have clinical meaning and help our customers in their daily lives is IBA’s No. 1 priority.”
Dr. Lane Rosen, Medical Director at Willis-Knighton Cancer Center added: “IBA is recognized as a company that listens to its customers. With the latest large field of view onboard CBCT scan, they have achieved a technological advancement with an easy workflow that helps to provide greater precision for patients at WKHS and other centers.”
CBCT imaging with a large-field-of-view is the first step of many planned developments in imaging; further consolidating IBA’s leadership role in every aspect of radiation therapy.
*Proteus®ONE is the brand name of a configuration of the Proteus®235 in the US and Europe and a certified product in Japan.
**Proteus®PLUS is the brand name of a configuration of the Proteus®235.
IBA: first large field-of-view cone-beam CT for proton therapy ready for commissioning. Appl Rad Oncol.